Albert Bourla, Pfizer CEO (Matthew Busch/Bloomberg via Getty Images)
November 17, 2022 11:07 AM EST
Coronavirus

As bi­va­lent boost­er up­take crawls, Pfiz­er and BioN­Tech start ear­ly-stage pan-vari­ant tri­al

Lei Lei Wu

News Reporter

Pfiz­er and BioN­Tech an­nounced Thurs­day morn­ing that they be­gan a Phase I tri­al of a new pan-vari­ant Covid vac­cine com­bined with their Omi­cron-spe­cif­ic boost­er, hope­ful­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

Is there room for MASH drugs in a GLP-1 world?

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times